Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Hahn

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Medizinrecht : Medr|May 13, 2020
Erik Hahn
Journal of Binocular Vision and Ocular Motility|June 4, 2019
A Comparison of the Maximum Deviation Measured in Intermittent Exotropia Using Various Clinical ConditionsKailee Algee, Leah Walsh, Erik Hahn
Molecular Microbiology|June 20, 2014
Adaptor bypass mutations of Bacillus subtilis spx suggest a mechanism for YjbH-enhanced proteolysis of the regulator Spx by ClpXPChio Mui Chan, Erik Hahn, Peter Zuber
Pharmacology Research & Perspectives|September 30, 2023
A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [<sup>14</sup> C] encorafenib in healthy male subjectsLance Wollenberg, Erik Hahn, Jason Williams, et al.
Vision (Basel, Switzerland)|April 30, 2021
Preoperative Variables Associated with Surgical Outcome for the Correction of ExodeviationDominique Salh, Leah Walsh, Erik Hahn, et al.
Biointerphases|September 22, 2017
Enhanced capture of bacteria and endotoxin by antimicrobial WLBU2 peptide tethered on polyethylene oxide spacersRamya Raman, Miranda A Raper, Erik Hahn, et al.
Pharmacology Research & Perspectives|January 31, 2025
The Absorption, Distribution, Metabolism, and Excretion of Binimetinib Following a Single Oral Dose of [<sup>14</sup>C]Binimetinib 45 mg in Healthy Male ParticipantsDustin Huynh, Erik Hahn, Micaela B Reddy, et al.
Clinical and Translational Science|October 14, 2023
Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutationsErik Hahn, Renae Chavira, Lance Wollenberg, et al.
Clinical Pharmacokinetics|June 23, 2025
Pharmacokinetics of Binimetinib in Participants with Hepatic ImpairmentJoseph Piscitelli, Erik Hahn, Lance Wollenberg, et al.
Journal of Molecular Biology|November 6, 2002
Exploring the 3D molecular architecture of Escherichia coli type 1 piliErik Hahn, Peter Wild, Uta Hermanns, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Medizinrecht : Medr|May 13, 2020
Erik Hahn
Journal of Binocular Vision and Ocular Motility|June 4, 2019
A Comparison of the Maximum Deviation Measured in Intermittent Exotropia Using Various Clinical ConditionsKailee Algee, Leah Walsh, Erik Hahn
Molecular Microbiology|June 20, 2014
Adaptor bypass mutations of Bacillus subtilis spx suggest a mechanism for YjbH-enhanced proteolysis of the regulator Spx by ClpXPChio Mui Chan, Erik Hahn, Peter Zuber
Pharmacology Research & Perspectives|September 30, 2023
A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [<sup>14</sup> C] encorafenib in healthy male subjectsLance Wollenberg, Erik Hahn, Jason Williams, et al.
Vision (Basel, Switzerland)|April 30, 2021
Preoperative Variables Associated with Surgical Outcome for the Correction of ExodeviationDominique Salh, Leah Walsh, Erik Hahn, et al.
Biointerphases|September 22, 2017
Enhanced capture of bacteria and endotoxin by antimicrobial WLBU2 peptide tethered on polyethylene oxide spacersRamya Raman, Miranda A Raper, Erik Hahn, et al.
Pharmacology Research & Perspectives|January 31, 2025
The Absorption, Distribution, Metabolism, and Excretion of Binimetinib Following a Single Oral Dose of [<sup>14</sup>C]Binimetinib 45 mg in Healthy Male ParticipantsDustin Huynh, Erik Hahn, Micaela B Reddy, et al.
Clinical and Translational Science|October 14, 2023
Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutationsErik Hahn, Renae Chavira, Lance Wollenberg, et al.
Clinical Pharmacokinetics|June 23, 2025
Pharmacokinetics of Binimetinib in Participants with Hepatic ImpairmentJoseph Piscitelli, Erik Hahn, Lance Wollenberg, et al.
Journal of Molecular Biology|November 6, 2002
Exploring the 3D molecular architecture of Escherichia coli type 1 piliErik Hahn, Peter Wild, Uta Hermanns, et al.
Pageof 2